351 related articles for article (PubMed ID: 12754207)
21. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor.
Jo M; Thomas KS; O'Donnell DM; Gonias SL
J Biol Chem; 2003 Jan; 278(3):1642-6. PubMed ID: 12426305
[TBL] [Abstract][Full Text] [Related]
23. Gangliosides inhibit urokinase-type plasminogen activator (uPA)-dependent squamous carcinoma cell migration by preventing uPA receptor/alphabeta integrin/epidermal growth factor receptor interactions.
Wang XQ; Sun P; Paller AS
J Invest Dermatol; 2005 Apr; 124(4):839-48. PubMed ID: 15816844
[TBL] [Abstract][Full Text] [Related]
24. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
25. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
[TBL] [Abstract][Full Text] [Related]
26. A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.
Hillig T; Engelholm LH; Ingvarsen S; Madsen DH; Gårdsvoll H; Larsen JK; Ploug M; Danø K; Kjøller L; Behrendt N
J Biol Chem; 2008 May; 283(22):15217-23. PubMed ID: 18362146
[TBL] [Abstract][Full Text] [Related]
27. Sequences within domain II of the urokinase receptor critical for differential ligand recognition.
Li Y; Lawrence DA; Zhang L
J Biol Chem; 2003 Aug; 278(32):29925-32. PubMed ID: 12761227
[TBL] [Abstract][Full Text] [Related]
28. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
[TBL] [Abstract][Full Text] [Related]
29. Urokinase-type plasminogen activator receptor (uPAR) ligation induces a raft-localized integrin signaling switch that mediates the hypermotile phenotype of fibrotic fibroblasts.
Grove LM; Southern BD; Jin TH; White KE; Paruchuri S; Harel E; Wei Y; Rahaman SO; Gladson CL; Ding Q; Craik CS; Chapman HA; Olman MA
J Biol Chem; 2014 May; 289(18):12791-804. PubMed ID: 24644284
[TBL] [Abstract][Full Text] [Related]
30. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
Ploug M
Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
[TBL] [Abstract][Full Text] [Related]
31. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner.
Nguyen DH; Catling AD; Webb DJ; Sankovic M; Walker LA; Somlyo AV; Weber MJ; Gonias SL
J Cell Biol; 1999 Jul; 146(1):149-64. PubMed ID: 10402467
[TBL] [Abstract][Full Text] [Related]
32. Potential role of kringle-integrin interaction in plasmin and uPA actions (a hypothesis).
Takada Y
J Biomed Biotechnol; 2012; 2012():136302. PubMed ID: 23125522
[TBL] [Abstract][Full Text] [Related]
33. Regulation of urokinase receptor function and pericellular proteolysis by the integrin alpha(5)beta(1).
Bass R; Ellis V
Thromb Haemost; 2009 May; 101(5):954-62. PubMed ID: 19404550
[TBL] [Abstract][Full Text] [Related]
34. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo.
May AE; Kanse SM; Lund LR; Gisler RH; Imhof BA; Preissner KT
J Exp Med; 1998 Sep; 188(6):1029-37. PubMed ID: 9743521
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
36. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
Liang OD; Chavakis T; Kanse SM; Preissner KT
J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
[TBL] [Abstract][Full Text] [Related]
37. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
[TBL] [Abstract][Full Text] [Related]
38. Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells.
Alfano M; Mariani SA; Elia C; Pardi R; Blasi F; Poli G
Blood; 2009 Feb; 113(8):1699-709. PubMed ID: 18941116
[TBL] [Abstract][Full Text] [Related]
39. Regulation of urokinase receptor proteolytic function by the tetraspanin CD82.
Bass R; Werner F; Odintsova E; Sugiura T; Berditchevski F; Ellis V
J Biol Chem; 2005 Apr; 280(15):14811-8. PubMed ID: 15677461
[TBL] [Abstract][Full Text] [Related]
40. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility.
Nguyen DH; Hussaini IM; Gonias SL
J Biol Chem; 1998 Apr; 273(14):8502-7. PubMed ID: 9525964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
